Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of Viral Genome to Assembly Sites.

Résumé : Daclatasvir is a direct-acting antiviral agent and potent inhibitor of NS5A, which is involved in replication of the hepatitis C virus (HCV) genome, presumably via membranous web shaping, and assembly of new virions, likely via transfer of the HCV RNA genome to viral particle assembly sites. Daclatasvir inhibits the formation of new membranous web structures and, ultimately, of replication complex vesicles, but also inhibits an early assembly step. We investigated the relationship between daclatasvir-induced clustering of HCV proteins, intracellular localization of viral RNAs and inhibition of viral particle assembly.
Liste complète des métadonnées

Littérature citée [2 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01425689
Contributeur : Bertrand Boson <>
Soumis le : lundi 6 mars 2017 - 10:11:57
Dernière modification le : jeudi 29 mars 2018 - 11:16:01

Fichier

1-s2.0-S0016508516354476-main....
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Bertrand Boson, Solène Denolly, Fanny Turlure, Christophe Chamot, Marlène Dreux, et al.. Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of Viral Genome to Assembly Sites.. Gastroenterology, WB Saunders, 2016, 152 (4), pp.895-907. 〈10.1053/j.gastro.2016.11.047〉. 〈inserm-01425689v2〉

Partager

Métriques

Consultations de la notice

287

Téléchargements de fichiers

128